# A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

> **NCT06930664** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 146 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Sotatercept
- **BIOLOGICAL:** Sotatercept Autoinjector

## Key facts

- **NCT ID:** NCT06930664
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-16
- **Primary completion:** 2025-11-11
- **Final completion:** 2025-11-25
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930664, "A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06930664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*